

HEDGEYE

Health Care Position Monitor Update

March 23, 2020



B. Rich — HEDGEYE



Hedgeye Health Care

Tom Tobin, Managing Director, Health Care

Ttobin@Hedgeye.com

@HedgeyeHC

Emily Evans, Managing Director, Health Policy

Eevans@Hedgeye.com

@HedgeyeEEvans

William McMahon, Analyst, Health Care

Wcmahon@Hedgeye.com

DISCLAIMER

Hedgeye Risk Management, LLC (“Hedgeye”) is a registered investment advisor, registered with the State of Connecticut. Hedgeye is not a broker dealer and does not provide investment advice to individuals. This research does not constitute an offer to sell, or a solicitation of an offer to buy any security or investment vehicle. This research is presented without regard for individual investment preferences or risk parameters; it is general information and does not constitute specific investment advice, nor does it constitute or contain any legal or tax opinions. This presentation is based on information from sources believed to be reliable. Hedgeye is not responsible for errors, inaccuracies or omissions of information. The opinions and conclusions contained in this report are those of the individual expressing those opinions or conclusion and are intended solely for the use of Hedgeye’s clients and subscribers, and the authorized recipients of the content. In reaching its own opinions and conclusions, Hedgeye and its employees have relied upon research conducted by Hedgeye’s employees, which is based upon sources considered credible and reliable within the industry. Neither Hedgeye, nor its employees nor any individual expressing opinions, conclusions or data are responsible for the validity or authenticity of the information upon which it has relied.

TERMS OF USE

This report is protected by United States and foreign copyright laws and is intended solely for the use of its authorized recipient. Access must be provided directly by Hedgeye. There is a fee associated with access to this report and the information and materials presented during the event. **Redistribution or republication of this report and its contents are strictly prohibited.** By joining this call or possessing these materials, you agree to these Terms. For more detail please refer to the appropriate sections of the Hedgeye Services Agreement and the Terms of Service at https://www.hedgeye.com/terms_of_service.

Health Care Position Monitor

HEDGEYE

For Week of March 23, 2020

Best Ideas - Longs						Best Ideas - Shorts					
LONG		Price	Mkt Cap (\$B)	Trend	Tail	SHORT		Price	Mkt Cap (\$B)	Trend	Tail
Active Longs						Active Shorts					
TDOC	Teladoc Health, Inc.	\$ 141.74	\$10.3B	√	√	EXAS	Exact Sciences Corporation	\$ 51.61	\$7.6B	×	×
AMN	AMN Healthcare Services, Inc.	\$ 62.75	\$2.9B	√		HQY	HealthEquity Inc	\$ 44.31	\$3.1B	×	×
GH	Guardant Health, Inc.	\$ 64.05	\$6.0B	√		NVTA	Invitae Corp.	\$ 10.15	\$1.0B	×	×
Long Bias						Short Bias					
ONEM	1Life Healthcare, Inc.	\$ 19.49	\$2.4B			HCA	HCA Healthcare Inc	\$ 78.50	\$26.6B		
						DVA	DaVita Inc.	\$ 64.99	\$8.2B		



Disclaimer

Hedgeye's "bias" represents Hedgeye's outlook on companies currently under Hedgeye's review, or for which timing is not right for greater coverage. Hedgeye may or may not provide further commentary on any or all companies represented on the bench and representation of a company on the bench does not forecast whether Hedgeye will or will not issue any additional material on that company.

Telemedicine take off


New users 1.5X existing users, potential users > 10X existing users

Q1: Have you cancelled an office-based doctor visit in the last 30 days? (Percentage of those with an appointment)



AMN Tracker


New per Day, Quarterly



The trend in new listings per day has been elevated over 1Q20. The incremental demand from COVID-19 has yet to impact the series visibly.

Shutting down the movement of people has so far not diminished incremental indicator of demand.


Active Job Listings, Quarterly



“Active” listings may be misleading as we count listings that fall off as having been placed. It is just as likely that cancelations lead to an increase, but with new listings running up, that is less probable in our view.

AMN Tracker | ICU RN Job Listings


Early COVID-19 Outbreak Cities, New Listings, Monthly



In COVID-19 cities, new listings for ICU RNs is running dramatically higher compared to what was a solid flu season in 2019-2020.

AMN Tracker | ICU RN Job Listings


Early COVID-19 Outbreak States, New Listings, Monthly



In COVID-19 outbreak states, the demand is widespread for ICU-RN staff.

AMN Tracker | Open ICU RN Job Listings


Early COVID-19 Outbreak Cities vs National, New Listings, Monthly



Compared to the outbreak cities, the national trend has been slowing for ICU RN listings. We assume the national trend divergence with outbreak cities in 2020 is directly related to COVID-19.

COVID-19 Research



Scientists have published 1,800 studies since October 2019



Research and collaboration has been on display as the global scientific community responds to the COVID-19 crisis.

Clinical trials COVID-19

Studies and enrollment are ramping, #Remdesivir, #Hydrochloroquine, data still weeks away



Drugs treatments coming into focus

Dampen the patient acuity and mortality and we might spare the system

New Results

[Comment on this paper](#)

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

David E. Gordon, Gwendolyn M. Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Matthew J O'Meara, Jeffrey Z. Guo, Danielle L. Swaney, Tia A. Tummino, Ruth Huttenhain, Robyn Kaake, Alicia L. Richards, Beril Tutuncuoglu, Helene Foussard, Jyoti Batra, Kelsey Haas, Maya Modak, Minkyu Kim, Paige Haas, Benjamin J. Polacco, Hannes Braberg, Jacqueline M. Fabius, Manon Eckhardt, Margaret Soucheray, Melanie Brewer, Merve Cakir, Michael J. McGregor, Qiongyu Li, Zun Zar Chi Naing, Yuan Zhou, Shiming Peng, Ilsa T. Kirby, James E. Melnyk, John S Chorba, Kevin Lou, Shizhong A. Dai, Wenqi Shen, Ying Shi, Ziyang Zhang, Inigo Barrio-Hernandez, Danish Memon, Claudia Hernandez-Armenta, Christopher J.P. Mathy, Tina Perica, Kala B. Pilla, Sai J. Ganesan, Daniel J. Saltzberg, Rakesh Ramachandran, Xi Liu, Sara B. Rosenthal, Lorenzo Calviello, Srivats Venkataramanan, Yizhu Lin, Stephanie A. Wankowicz, Markus Bohn, Raphael Trenker, Janet M. Young, Devin Caverio, Joe Hiatt, Theo Roth, Ujjwal Rathore, Advait Subramanian, Julia Noack, Mathieu Hubert, Ferdinand Roesch, Thomas Vallet, Björn Meyer, Kris M. White, Lisa Miorin, David Agard, Michael Emerman, Davide Ruggero, Adolfo Garcia-Sastre, Natalia Jura, Mark von Zastrow, Jack Taunton, Olivier Schwartz, Marco Vignuzzi, Christophe d'Enfert, Shaeri Mukherjee, Matt Jacobson, Harmit S. Malik, Danica G Fujimori, Trey Ideker, Charles S Craik, Stephen Floor, James S. Fraser, John Gross, Andrej Sali, Tanja Kortemme, Pedro Beltrao, Kevan Shokat, Brian K. Shoichet, Nevan J. Krogan

doi: <https://doi.org/10.1101/2020.03.22.002386>

Abstract

An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 290,000 people since the end of 2019, killed over 12,000, and caused worldwide social and economic disruption. There are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Unfortunately, the scientific community has little knowledge of the molecular details of SARS-CoV-2 infection. To illuminate this, we cloned, tagged and expressed 26 of the 29 viral proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), which identified 332 high confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays. The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains.